8-K: atai Life Sciences Announces Pricing of Public Offering of Common Shares at $2.10 per Share

atai Life Sciences has priced a public offering of 26,190,477 common shares at $2.10 per share, expecting gross proceeds of approximately $55 million.

Summary

• atai Life Sciences announced the pricing of a public offering of 26,190,477 common shares at $2.10 per share.
• The offering includes an underwriter option to purchase an additional 3,928,571 common shares.
• The gross proceeds are expected to be approximately $55 million before deducting underwriting discounts, commissions, and other offering expenses.
• atai intends to use the net proceeds for general corporate purposes, including working capital and advancing the clinical development of its product candidates and programs.
• The offering is expected to close on February 14, 2025, subject to customary closing conditions.
• Berenberg is acting as the sole bookrunner for the offering.
• The company estimates that its cash, short-term securities, public equity holdings, and committed term loan facility will be sufficient to fund its operating expenses into 2027.
• In December 2024, Beckley Psytech Limited, a company in which atai made a 35.5% strategic investment in 2024, publicly announced positive topline results from its open-label Phase IIa study of ELE-101 in six patients with Major Depressive Disorder.
• In January 2025, Beckley Psytech publicly announced positive topline findings from its open-label Phase IIa study of BPL-003 in twelve patients with moderate-to-severe Alcohol Use Disorder.
• In January 2025, atai initiated an exploratory, randomized, double-blind, placebo-controlled Phase 2 study in the United Kingdom to assess the safety, tolerability and efficacy of EMP-01 in adults with SAD.
• Recognify Life Sciences, Inc., a company in which atai has a 51.9% strategic investment, is currently conducting a Phase 2b proof-of-concept clinical trial in the United States for RL-007 in 234 patients with cognitive impairment associated with schizophrenia (CIAS).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The announcement of a public offering is generally viewed as a positive development for a company, as it provides access to capital to fund its operations and growth. The positive results from Phase IIa studies of ELE-101 and BPL-003 are also encouraging. However, the risks and uncertainties associated with the company's business should be considered.

Positives

• The public offering will provide atai Life Sciences with approximately $55 million in gross proceeds to fund its operations and clinical development programs.
• The company has the option to raise additional capital if the underwriter exercises its option to purchase additional shares.
• The company estimates that its cash, short-term securities, public equity holdings, and committed term loan facility will be sufficient to fund its operating expenses into 2027.
• Beckley Psytech, in which atai has a 35.5% stake, announced positive results from Phase IIa studies of ELE-101 for Major Depressive Disorder and BPL-003 for Alcohol Use Disorder.
• Recognify Life Sciences, in which atai has a 51.9% stake, is conducting a Phase 2b trial for RL-007 in patients with cognitive impairment associated with schizophrenia.

Negatives

• The public offering will dilute existing shareholders' ownership.
• The company's stock price may be negatively impacted by the increased supply of shares in the market.
• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• The company's estimate that its cash, short-term securities, public equity holdings, and committed term loan facility will be sufficient to fund its operating expenses into 2027 is based on assumptions that may prove to be incorrect.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur as expected.
• The company's ability to successfully develop and commercialize its product candidates is subject to significant risks and uncertainties, including clinical trial failures, regulatory hurdles, and competition from other companies.
• The company's estimate that its cash, short-term securities, public equity holdings, and committed term loan facility will be sufficient to fund its operating expenses into 2027 is based on assumptions that may prove to be incorrect, and the company could use its available capital resources sooner than it currently expects.
• The company's investments in Beckley Psytech and Recognify Life Sciences are subject to the risks and uncertainties associated with those companies' businesses.
• The company faces risks related to intellectual property, cybersecurity, and compliance with healthcare laws.

Future Outlook

atai intends to use the net proceeds from this offering for general corporate purposes, including for working capital and to advance the clinical development of its product candidates and programs. The Company estimates that its cash, short-term securities, public equity holdings, and committed term loan facility will be sufficient to fund its operating expenses into 2027.

Industry Context

atai Life Sciences operates in the biopharmaceutical industry, specifically focusing on mental health disorders. The company is developing novel therapeutics to address unmet needs in the treatment of depression, anxiety, and other mental health conditions. The industry is characterized by high research and development costs, regulatory hurdles, and competition from other companies developing similar therapies.

Comparison to Industry Standards

• The public offering is a common method for biopharmaceutical companies to raise capital to fund their research and development activities.
• The offering price of $2.10 per share is within the typical range for similar companies in the industry.
• The company's stated intention to use the net proceeds for general corporate purposes and to advance the clinical development of its product candidates and programs is consistent with industry practices.
• The company's investments in Beckley Psytech and Recognify Life Sciences are examples of strategic partnerships and collaborations that are common in the biopharmaceutical industry.
• Comparable companies that have recently conducted public offerings include Mind Medicine (MindMed) Inc., Compass Pathways plc, and GH Research PLC.

Stakeholder Impact

• Shareholders will experience dilution as a result of the public offering.
• Employees may benefit from the increased financial stability of the company.
• Customers may benefit from the company's ability to advance the clinical development of its product candidates and programs.
• Suppliers may benefit from the increased demand for their products and services.
• Creditors may benefit from the increased financial stability of the company.

Next Steps

• The offering is expected to close on February 14, 2025, subject to customary closing conditions.
• atai intends to use the net proceeds from this offering for general corporate purposes, including for working capital and to advance the clinical development of its product candidates and programs.
• The company expects to randomize the first patient in the second quarter of 2025 for the Phase 2 study of EMP-01 for Social Anxiety Disorder.

Key Dates